| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Electra Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.9M | Series C | 10/22/2025 | $184.13M | $460.97M | $6.77 | Nextech, EQT Life Sciences, Sanofi, HBM Healthcare Investments, Mubadala Capital, OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, RA Capital Management | ||||
 | Levels | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.48M | Series A-1 | 4/20/2022 | $46.01M | $311.7M | $10.44 | Andrea Funsten, Ben Gilbert, David Rosenthal, Lenny Rachitsky, Mario Gabriele, Mat Fraser, Moshe Lifschitz, Niv Dror, Andreessen Horowitz, Trust Ventures, Shrug Capital, TriplePoint Capital, Long Journey Ventures | ||||
 | Dandy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $6.96M | Series Seed-1 | 11/14/2019 | $2.63M | $10.41M | $0.51 | The MBA Fund, Indicator Ventures, RiverPark Ventures, Human Capital | ||||
 | Paradromics | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $383.00K | -- | 3 | -- | Not available | -- | -- | $105M | Series A-3 | 2/12/2025 | $15.78M | $499.98M | $1.17 | NEOM Investment Fund, Kaleida Capital, Leo Lion, Prime Movers Lab, Wescott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, Alpha Edison, Green Sands Equity | ||||
 | Pelage | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $227.00K | -- | 2 | -- | Not available | -- | -- | $150.75M | Series B | 10/15/2025 | $120M | $314.7M | $7.23 | ARCH Venture Partners, GV, Main Street Advisors, Visionary Ventures, YK Bioventures | ||||
 | Galileo Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $265.94M | Series F | 8/14/2026 | $30.13M | $387.07M | $3.68 | Undisclosed Investors | ||||
 | Apnimed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $249.52M | Series D-1 | 3/11/2026 | $25M | $491.51M | $13.03 | Undisclosed Investors | ||||
 | Calm | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $164.14M | Series 1 | 2/29/2024 | $25.07M | $322.29M | $2.38 | Undisclosed Investors | ||||
 | Quip | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $569.90K | -- | 1 | Not available | -- | -- | $76.99M | Series C-3 | 1/29/2024 | $2.82M | $190.39M | $2.46 | Undisclosed Investors | ||||
 | Human Longevity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.95M | Series B-1 | 8/21/2024 | $32M | $185.79M | $0.31 | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | ||||
 | SmithRx | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.84M | Series C | 1/23/2024 | $60M | $354.68M | $3.76 | Venrock | ||||
 | Octave | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.68M | Series C-3 | 2/1/2024 | $5M | $208.27M | $1.95 | Felicis | ||||
 | Headspace | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $74.08M | Series B | 7/3/2017 | $38.65M | $298.33M | $1.93 | Spectrum Equity | ||||
 | Happy Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $63.16M | Series B-1 | 8/18/2026 | $26.14M | $47.78M | $1.92 | ARCH Venture Partners, OpenLoop | ||||
 | Tia | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.48M | Series D-1 | 9/30/2025 | $20M | $87.68M | $0.24 | Undisclosed Investors | ||||
 | Triveni Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $297.49M | Series C | 6/17/2026 | $65.25M | $423.44M | $1.26 | Ascenta Capital, Janus Henderson Investors, Deep Track Capital, OrbiMed, Atlas Venture, Viking Global Investors | ||||
 | Unlearn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $135.17M | Series C | 2/8/2024 | $50M | $368.17M | $9.24 | Altimeter Capital Management, Radical Ventures, Mubadala Capital, Wittington Ventures, EPIC Ventures, Necessary Ventures, Insight Partners, 8VC, DCVC | ||||
 | Gameto | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117M | Series C | 8/12/2025 | $44M | $234.3M | $7.31 | Overwater Ventures, Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia | ||||
 | Syllable | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $298.1M | Series MA | 3/21/2024 | $22M | $414.31M | $2.31 | TT Capital Partners | ||||
 | Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.46M | Series C | 10/31/2024 | $115.5M | $346.35M | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | ||||
 | Akido | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $106.75M | Series B | 5/15/2025 | $60M | $373.15M | $13.45 | Oak HC/FT, Greco, SNR, Y Combinator, Future Communities Capital, Jeff Dean, Comprehensive Blood & Cancer Center | ||||
 | DeepScribe | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $59.19M | Series B | 1/3/2024 | $24M | $134.68M | $3.45 | Undisclosed Investors | ||||
 | Mesh Optical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $50M | Series A-1 | 2/17/2026 | $37.93M | $253.44M | $16.17 | Thrive Capital, Also Capital, Banner Ventures | ||||
 | Obsidian Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $329.03M | Series C | 4/3/2024 | $160.5M | $480.83M | $1.90 | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | ||||